Reviewed listing: NASDAQ:CAI · Analysis dated Oct 22, 2026
How does the company make money?
Caris analyzes tumor tissue and blood for molecular characteristics. This information helps doctors select cancer treatments and pharmaceutical companies with research and development.
What supports the business?
Quarterly revenue rose by about 45%; the prior-year operating loss turned into income of 26.93 million USD. This shows that higher patient volumes and improved reimbursement are improving economics.
What could improve?
More tests and better cost utilization could convert a larger share of revenue into free cash flow. Reimbursement, demand, and costs must all remain favorable for that to happen.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
32.35 USD are expensive. Only in 3 years does my base case yield 19.83 USD per share. At a required annual return of 12%, that corresponds to a current price ceiling of 14.10 USD; the stored share price is above it.
What is the main risk?
Payers may change reimbursement and access to tests. High stock compensation, competition, and investment may prevent revenue growth from translating into a proportional benefit for shareholders.
What is the overall assessment?
Caris is growing rapidly and now reports positive operating results. However, the share price of 32.35 USD already requires a substantial further increase in sustainable earnings and cash inflows; there is not enough margin of safety for that.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in